Steven Katz, M.D.

Chief Medical Officer
TriSalus Life Sciences

Presentation(s):

• Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors

  Monday, March 6, 2023
  4:12 PM – 4:21 PM

  Disclosure information not submitted.

• Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.

  Wednesday, March 8, 2023
  3:36 PM – 3:45 PM

  Disclosure information not submitted.